【レポートの概要（一部）】
1. Report Overview
1.1 Global Asthma and COPD Therapies Market Overview
1.2 Global Asthma and COPD Therapies Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Asthma and COPD Therapies
2.1 The Pharmaceutical Industry: A Very Brief Overview
2.2 Overview of Respiratory Diseases
2.2.1 Classifying Respiratory Diseases: Obstructive and Restrictive
2.3 What Is Asthma?
2.3.1 Trends in Asthma Prevalence
2.3.2 Pathophysiology of Asthma
2.3.3 Symptoms of Asthma
2.3.4 Causes and Triggers for Asthma
2.3.5 Treatment of Asthma
2.3.6 Guidelines for Asthma Treatment
2.3.7 Drug Treatments for Asthma
2.3.8 Drug Delivery Methods in Asthma
2.4 What Is Chronic Obstructive Pulmonary Disease (COPD)?
2.4.1 Trends in COPD Prevalence
2.4.2 Pathophysiology of COPD
2.4.3 Signs and Symptoms of COPD
2.4.4 Treatment of COPD
2.4.5 Drug Treatments for COPD
2.4.6 Guidelines for COPD Treatment
2.5 Major Drug Classes in the Treatment of Asthma and COPD
2.5.1 Bronchodilators
2.5.1.1 Beta2-Agonists
2.5.1.2 Anticholinergics
2.5.2 Anti-Inflammatory Drugs
2.5.2.1 Corticosteroids
2.5.2.2 Leukotriene Receptor Antagonists
2.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease
2.5.3 Combination Drugs
2.6 Phases of Clinical Trials
2.7 Scope of this Report
2.8 Currency Exchange Rates in This Report
3. Asthma and COPD Therapies: World Market 2015-2025
3.1 The World Respiratory Drugs Market by Therapeutic Area
3.2 The World Asthma and COPD Therapies Market in 2014
3.2.1 Leading Asthma and COPD Therapies
3.2.2 Leading Companies in the Asthma and COPD Therapies Market
3.3 World Asthma and COPD Therapies Market: Sales Forecast by Therapeutic Area, 2015-2025
3.3.1 World Asthma Therapies Market: Sales Forecast 2015-2025
3.3.2 World COPD Therapies Market: Sales Forecast 2015-2025
3.4 World Asthma and COPD Therapies Market: Sales Forecast by Drug Class 2015-2025
3.5 Combination Drugs Lead the Asthma and COPD Therapies Market
3.6 How Will Segmental Market Shares Change to 2025?
3.6.1 World Asthma and COPD Therapies Market: Drivers and Restraints 2015-2025
3.7 Asthma and COPD Therapies: Trends and Developments
3.7.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers
3.7.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?
4. Leading National Markets 2015-2025
4.1 Regional Breakdown of the World Asthma and COPD Therapies Market
4.2 World Asthma and COPD Therapies Market: Regional Forecast 2015-2025
4.2.1 How Will Regional Market Shares Change to 2025?
4.3 National Breakdown of the World Asthma and COPD Therapies Market
4.4 World Asthma and COPD Therapies Market: National Markets Forecast 2015-2025
4.4.1 How Will National Market Shares Change to 2025?
4.5 The US Asthma and COPD Therapies Market 2015-2025
4.5.1 US Asthma and COPD Therapies Market Forecast 2015-2025
4.5.2 US Asthma and COPD Therapies Market: Trends and Developments
4.5.2.1 Increasing COPD Prevalence in the US
4.5.2.2 FDA Issues Draft Guidance on Generic Inhaler Bioequivalence
4.5.2.3 Pharmacy Benefit Managers Alter Formulary Status of Advair
4.6 Japanese Asthma and COPD Therapies Market 2015-2025
4.6.1 Japanese Asthma and COPD Therapies Market Forecast 2015-2025
4.6.2 Japanese Asthma and COPD Therapies Market: Trends and Developments
4.6.2.1 Generic Penetration to Reach 60% by 2018?
4.6.2.2 Japanese Pharmaceutical Industry Regulatory Reform
4.7 EU5 Asthma and COPD Therapies Market 2015-2025
4.7.1 German Asthma and COPD Therapies Market Forecast 2015-2025
4.7.2 French Asthma and COPD Therapies Market Forecast 2015-2025
4.7.3 UK Asthma and COPD Therapies Market Forecast 2015-2025
4.7.4 Italian Asthma and COPD Therapies Market Forecast 2015-2025
4.7.5 Spanish Asthma and COPD Therapies Market Forecast 2015-2025
4.7.6 EU5 Asthma and COPD Therapies Market: Trends and Developments
4.7.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law
4.7.6.2 France: Social Security Finance Bill 2015
4.7.6.3 UK: Improving Asthma and COPD Patient Outcomes
4.7.6.4 Italy: Austerity Measures Limiting Growth
4.7.6.5 Spain: The Start of Recovery in the Spanish Economy
4.8 BRIC Asthma and COPD Therapies Market 2015-2025
4.8.1 Chinese Asthma and COPD Therapies Market Forecast 2015-2025
4.8.2 Chinese Asthma and COPD Therapies Market: Trends and Developments
4.8.2.1 China’s Industrial Future and Asthma/COPD
4.8.2.2 Expansion of Healthcare Coverage and Reimbursement
4.8.2.3 Price Controls and the Anhui Model
4.8.3 Brazilian Asthma and COPD Therapies Market Forecast 2015-2025
4.8.4 Brazilian Asthma and COPD Therapies Market: Trends and Developments
4.8.4.1 Increasing Access to Medicines
4.8.5 Indian Asthma and COPD Therapies Market Forecast 2015-2025
4.8.6 Indian Asthma and COPD Therapies Market: Trends and Developments
4.8.6.1 Drug Prices Control Order 2014
4.8.6.2 Expansion of Healthcare Provision
4.8.7 Russian Asthma and COPD Therapies Market Forecast 2015-2025
4.8.8 Russian Asthma and COPD Therapies Market: Trends and Developments
4.8.8.1 No Embargo on Foreign Drug Imports
4.8.8.2 Pharma2020 and the Russian Pharmaceutical Industry
4.9 Mexican Asthma and COPD Therapies Market 2015-2025
4.9.1 Mexican Asthma and COPD Therapies Market Forecast 2015-2025
4.9.2 Mexican Asthma and COPD Therapies Market: Trends and Developments
4.9.2.1 Seguro Popular: Mexican Healthcare Reform
4.9.2.2 COFEPRIS: Regulatory Changes and Improvements
4.9.2.3 Mexico’s Agreement for Innovation
5. Bronchodilator Monotherapy Market 2015-2025
5.1 Introduction to Bronchodilator Monotherapy
5.2 The Bronchodilator Monotherapy Market in 2014
5.2.1 Leading Bronchodilators in 2014
5.3 Bronchodilator Monotherapy: Market Forecast 2015-2025
5.4 How Will Market Shares by Drug Class Change to 2025?
5.5 The Short-Acting Beta2-Agonist (SABA) Market 2015-2025
5.5.1 Leading SABAs in 2014
5.5.2 SABAs: Market Forecast 2015-2025
5.5.3 Market Share of Leading SABAs to 2025
5.5.4 Ventolin (salbutamol, GSK)
5.5.4.1 Ventolin: Sales Forecast 2015-2025
5.5.5 ProAir (salbutamol, Teva)
5.5.5.1 ProAir: Sales Forecast 2015-2025
5.5.6 Proventil (salbutamol, Merck)
5.5.6.1 Proventil: Sales Forecast 2015-2025
5.5.7 Xopenex (levosalbutamol, Dainippon Sumitomo)
5.5.7.1 Xopenex: Sales Forecast 2015-2025
5.6 The Long-Acting Beta2-Agonist (LABA) Market 2015-2025
5.6.1 Leading LABAs in 2014
5.6.2 LABAs: Market Forecast 2015-2025
5.6.3 Market Share of Leading LABAs to 2025
5.6.4 Foradil (formoterol, Merck/Novartis)
5.6.4.1 Foradil: Sales Forecast 2015-2025
5.6.5 Brovana (salmeterol, GSK)
5.6.5.1 Brovana: Sales Forecast 2015-2025
5.6.6 Arcapta/Onbrez (indacaterol, Novartis)
5.6.6.1 Arcapta/Onbrez: Sales Forecast 2015-2025
5.6.7 Serevent (arfomoterol, Dainippon Sumitomo)
5.6.7.1 Serevent: Sales Forecast 2015-2025
5.7 The Anticholinergics Market 2015-2025
5.7.1 Leading Anticholinergics in 2014
5.7.2 Anticholinergics: Market Forecast 2015-2025
5.7.3 Market Share of Leading Anticholinergics to 2025
5.7.4 Spiriva (tiotropium, Boehringer Ingelheim)
5.7.4.1 Spiriva: Sales Forecast 2015-2025
5.7.5 Spiriva: Recent Developments
5.7.5.1 Safety Concerns and the UPLIFT Trial
5.7.5.2 Results of the POET Study
5.7.5.3 Competition from Combination Products
5.7.6 Atrovent (ipratropium, Boehringer Ingelheim)
5.7.6.1 Atrovent: Sales Forecast 2015-2025
5.7.7 Eklira/Tudorza/Bretaris (aclidinium, AstraZeneca/Menarini)
5.7.7.1 Eklira/Tudorza/Bretaris: Sales Forecast 2015-2025
6. Anti-Inflammatory Drugs Market 2015-2025
6.1 Introduction to Anti-Inflammatory Drugs
6.2 The Anti-Inflammatory Drugs Market in 2014
6.2.1 Leading Anti-Inflammatory Drugs in 2014
6.3 Anti-Inflammatory Drugs: Market Forecast 2015-2025
6.4 How Will Market Shares by Drug Class Change to 2025?
6.5 The Corticosteroids Market 2015-2025
6.5.1 Leading Corticosteroids in 2014
6.5.2 Corticosteroids: Market Forecast 2015-2025
6.5.3 Market Share of Leading Corticosteroids to 2025
6.5.4 Flixotide/Flovent (fluticasone propionate, GSK)
6.5.4.1 Flixotide/Flovent: Sales Forecast 2015-2025
6.5.5 Pulmicort (budesonide, AstraZeneca)
6.5.5.1 Pulmicort: Sales Forecast 2015-2025
6.5.6 QVAR (beclometasone, Teva)
6.5.6.1 QVAR: Sales Forecast 2015-2025
6.5.7 Asmanex (mometasone, Merck)
6.5.7.1 Asmanex: Sales Forecast 2015-2025
6.6 The Anti-Leukotrienes Market 2015-2025
6.6.1 Leading Anti-Leukotrienes in 2014
6.6.2 Anti-Leukotrienes: Market Forecast 2015-2025
6.6.2.1 Market Share of Leading Anti-Leukotrienes to 2025
6.6.3 Singulair (montelukast, Merck)
6.6.3.1 Singulair: Sales Forecast 2015-2025
6.7 The Monoclonal Antibodies Market 2015-2025
6.7.1 Monoclonal Antibodies: Market Forecast 2015-2025
6.7.1.1 Market Share of Leading Monoclonal Antibodies to 2025
6.7.2 Xolair (omalizumab, Novartis/Roche)
6.7.2.1 Xolair: Sales Forecast 2015-2025
6.7.3 Cinquil (reslizumab, Teva)
6.7.3.1 Cinquil: Sales Forecast 2015-2025
6.7.4 Mepolizumab (Bosatria, GSK)
6.7.4.1 Mepolizumab: Sales Forecast 2015-2025
6.7.5 Benralizumab (MEDI-563, AstraZeneca/Kyowa Hakko Kirin)
6.7.5.1 Benralizumab: Sales Forecast 2015-2025
6.7.6 Lebrikizumab (RG3637, Roche)
6.7.6.1 Lebrikizumab: Sales Forecast 2015-2025
6.7.7 Dupilumab (REGN668, Regeneron/Sanofi)
6.7.7.1 Dupilumab: Sales Forecast 2015-2025
7. Combination Drugs Market 2015-2025
7.1 Introduction to Combination Drugs
7.1.1 Leading Combination Drugs in 2014
7.2 Combination Drugs: Market Forecast 2015-2025
7.3 How Will Market Shares by Drug Change to 2025?
7.3.1 Advair/Seretide (fluticasone/salmeterol, GSK)
7.3.1.1 Advair/Seretide: Sales Forecast 2015-2025
7.3.2 Symbicort (budesonide/formoterol fumarate, AstraZeneca)
7.3.2.1 Symbicort: Sales Forecast 2015-2025
7.3.2.2 Symbicort: The SMART Concept
7.3.3 Combivent (ipratropium/salbutamol, Boehringer Ingelheim)
7.3.3.1 Combivent: Sales Forecast 2015-2025
7.3.4 Dulera (formoterol/mometasone, Merck)
7.3.4.1 Dulera: Sales Forecast 2015-2025
7.3.5 Breo/Relvar Ellipta (vilanterol/fluticasone furoate, GSK)
7.3.5.1 Breo/Relvar: Sales Forecast 2015-2025
7.4 Recently Launched Combination Drugs
8. Leading Companies in the Asthma and COPD Therapies Market
8.1 Asthma and COPD Therapies: Increasing Competition
8.1.1 Leading Companies in Asthma and COPD in 2015
8.1.2 Leading Companies: Market Forecast 2015-2025
8.1.3 How Will Leading Companies’ Market Shares Change to 2025?
8.2 GSK
8.2.1 GSK: Asthma and COPD Therapies
8.2.2 GSK: Sales Forecast 2015-2025
8.2.3 GSK: Products in Development
8.2.4 GSK: Recent Developments
8.2.4.1 Recently Launched Combination Drugs
8.2.4.2 GSK Divests OTC Products
8.2.4.3 GSK Asset Swap with Novartis to Restructure Consumer Health
8.2.4.4 GSK Presents Data on Eosinophil Levels and COPD
8.3 Boehringer Ingelheim
8.3.1 Boehringer Ingelheim: Asthma and COPD Therapies
8.3.2 Boehringer Ingelheim: Sales Forecast 2015-2025
8.3.3 Boehringer Ingelheim: Asthma and COPD Product Development Ceased
8.3.4 Boehringer Ingelheim: Recent Developments
8.3.4.1 Expansion of Respimat Manufacturing Capacity
8.3.4.2 Respimat Safety Concerns and the TIOSPIR Study
8.3.4.3 Ben Venue Laboratories Shut Down
8.3.4.4 Sale of Roxane Laboratories
8.4 AstraZeneca
8.4.1 AstraZeneca: Asthma and COPD Therapies
8.4.2 AstraZeneca: Sales Forecast 2015-2025
8.4.3 AstraZeneca: Products in Development
8.4.4 AstraZeneca: Recent Developments
8.4.4.1 AstraZeneca Acquires Almirall’s Respiratory Portfolio
8.4.4.2 Acquisition of Pearl Therapeutics Expanded AstraZeneca’s Combination Drug Pipeline
8.4.4.3 AstraZeneca Rejects Pfizer Takeover Bid
8.4.4.4 AstraZeneca Acquires Right to Actavis’ Branded Respiratory Portfolio in US and Canada
8.5 Merck & Co. (Merck)
8.5.1 Merck: Asthma and COPD Therapies
8.5.2 Merck: Sales Forecast 2015-2025
8.5.3 Merck: Products in Development
8.5.4 Merck: Recent Developments
8.5.4.1 Bayer Acquires Merck’s Consumer Health Business
8.5.4.2 FDA Rejects Singulair OTC Switch
8.5.4.3 Takeda Ended Co-Promotion of Daxas with Merck
8.6 Novartis
8.6.1 Novartis: Asthma and COPD Therapies
8.6.2 Novartis: Sales Forecast 2015-2025
8.6.3 Novartis: Products in Development
8.6.4 Novartis: Recent Developments
8.6.4.1 Novartis Restructures Following Strategic Review
8.6.4.2 Novartis Presents Data on Ultibro and Seebri
8.6.4.3 Pfizer Promotes Two Novartis COPD drugs in the UK
8.7 Roche
8.7.1 Roche: Asthma and COPD Therapies
8.7.2 Roche: Sales Forecast 2015-2025
8.7.3 Roche: Products in Development
8.8 Teva
8.8.1 Teva: Asthma and COPD Therapies
8.8.2 Teva: Sales Forecast 2015-2025
8.8.3 Teva: Products in Development
8.8.4 Teva: Recent Developments
8.8.4.1 Launch of DuoResp Spiromax
9. Asthma and COPD Therapies Pipeline Analysis 2015-2025
9.1 A Strong Asthma and COPD Pipeline
9.2 The Bronchodilators Pipeline
9.2.1 Bronchodilators: Phase 3 Pipeline
9.2.1.1 PX1439 and PX1442 (Prosonix)
9.2.1.2 PT001 (glycopyrronium, AstraZeneca)
9.2.1.3 Spiriva Respimat (tiotropium, Boehringer Ingelheim)
9.2.1.4 GW642444 (vilanterol, GSK)
9.2.1.5 KRP-AB1102 (aclidinium, Kyorin Pharmaceutical)
9.2.1.6 Seebri Breezhaler (glycopyrronium, Novartis/Vectura)
9.2.1.7 QVAR BAI (beclometasone, Teva)
9.2.1.8 Albuterol MDPI/Albuterol Spiromax (salbutamol, Teva)
9.3 The Anti-Inflammatory Drugs Pipeline
9.3.1 Anti-Inflammatory Drugs: Phase 3 Pipeline
9.3.1.1 PSX1001 and PSX1050 (fluticasone propionate pMDI, Prosonix)
9.3.1.2 Masitinib (tyrosine kinase inhibitor, AB Science)
9.3.1.3 Inhaled Alpha-1 Antitrypsin (Kamada/Chiesi Farmaceutici)
9.3.1.4 VR506 (fluticasone propionate DPI, Vectura)
9.3.1.5 Favolir (budesonide, Vectura)
9.4 The Combination Drugs Pipeline
9.4.1 Combination Drugs: Phase 3 Pipeline
9.4.1.1 PSX2005 (fluticasone/salmeterol, Prosonix)
9.4.1.2 LAS40464 (aclidinium/formoterol, AstraZeneca)
9.4.1.3 PT003 (glycopyrronium/formoterol, AstraZeneca)
9.4.1.4 Tiotropium/Olodaterol Fixed-Dose Combination (LAMA/LABA, Boehringer Ingelheim)
9.4.1.5 Easyhaler Combination Drugs (Orion)
9.4.1.6 VR632 (ICS/LABA, Vectura/Sandoz)
9.5 Other Asthma and COPD Drugs Pipeline
10. Qualitative Analysis of the Asthma and COPD Therapies Market 2015-2025
10.1 SWOT Analysis of the Asthma and COPD Therapies Market
10.2 Strengths
10.2.1 Increasing Prevalence and Disease Burden
10.2.2 High Costs of Treatment
10.2.3 The Changing Perception of COPD
10.2.4 Patient Education: Understanding the Severity of Respiratory Disease
10.2.5 Lifecycle Management Strategies to Counter Patent Expiry
10.2.6 Advanced Inhaler Technologies to Counter Generic Erosion
10.2.7 Developments in Diagnostics
10.2.7.1 Diagnostic Imaging: Parametric Response Mapping for COPD
10.2.7.2 Biological Markers in COPD
10.3 Weaknesses
10.3.1 Under-Diagnosis: the ‘Ghost Population’
10.3.2 Side-Effects of Drug Classes
10.3.3 Patent Cliff for Devices
10.3.4 Low Patient Adherence
10.3.5 Costing Pressures in both Developed and Emerging Markets
10.4 Opportunities
10.4.1 Patient Phenotyping and Personalised Medicine
10.4.2 A Strong R&D Pipeline
10.4.2.1 Ultra-Long-Acting Beta2-Agonists
10.4.2.2 Muscarinic Antagonists and Beta2-Agonists (MABAs)
10.4.2.3 Monoclonal Antibodies
10.4.2.4 LAMA/LABA Combinations
10.4.3 Opportunities in Telehealth
10.5 Threats
10.5.1 Patent Expiry and Generic Competition
10.5.2 Pharmacy Benefit Managers and Cost Control
10.5.3 The WISDOM Trial Could Reduce Steroid Use in COPD
10.6 Porter’s Five Forces Analysis of the Asthma and COPD Therapies Market
10.6.1 Rivalry Among Competitors [Medium]
10.6.2 Threat of New Entrants [Medium]
10.6.3 Power of Suppliers [Medium]
10.6.4 Power of Buyers [High]
10.6.5 Threat of Substitutes [Low]
11. Research Interviews
11.1 Interview with Professor Clive Page, Professor of Pharmacology and Director of the Sackler Institute of Pulmonary Pharmacology, King’s College London
11.1.1 Treating Different Phenotypes of Asthma and COPD
11.1.2 Personalised Medicine and Improved Existing Drug Classes
11.1.3 Phenotyping of Asthma/COPD, Diagnosis and Treatment
11.1.4 WISDOM Trial: Questioning the Role of Steroids in COPD
11.1.5 Monoclonal Antibodies in Severe Asthma
11.1.6 Healthcare Costs and the Importance of Prevention
11.1.7 Areas to Improve Diagnosis and Treatment of Asthma
11.1.8 The Importance of Adherence and Early Diagnosis
11.1.9 Developments in Alpha-1 Antitrypsin Deficiency
11.1.10 Other Trends and Developments in Asthma and COPD
11.2 Interview with a Company Developing Pipeline Drugs for Asthma and COPD
11.2.1 Asthma and COPD Treatments in 2014-2024
11.2.2 Personalised Therapies for Asthma and COPD
11.2.3 Drivers and Restraints in the Market
11.2.4 The Outlook for the Asthma and COPD Market
12. Conclusions
12.1 Asthma and COPD Therapies: A Maturing Market
12.2 The World Asthma and COPD Therapies Market in 2014
12.2.1 Current Leading Asthma and COPD Therapies Segments
12.2.2 Leading Asthma and COPD Therapies
12.2.3 Leading Asthma and COPD Therapies Companies
12.2.4 Leading Regional and National Markets
12.3 World Asthma and COPD Therapies Market Forecast 2015-2025
12.4 The Future of the Asthma and COPD Therapies Market?
12.4.1 Growth in Anti-Inflammatory and Combination Drugs
12.4.2 Towards Personalised Medicine
12.4.3 Unmet Needs in Asthma and COPD
12.4.4 Strategies for Growth in 2015-2025
13. Glossary
Appendix A
Appendix B
【レポート販売概要】
■ タイトル：喘息及びCOPD（慢性閉塞性肺疾患）治療の世界市場予測：気管支拡張薬、抗炎症薬■ 英文：Asthma and COPD Therapies Market Forecast 2015-2025: Opportunities for Leading Companies
■ 発行日：2015年10月
■ 調査会社：visiongain
■ 商品コード：VGAIN5102610
■ 調査対象地域：グローバル
- 光触媒の世界市場：材料別（酸化亜鉛、二酸化チタン）、用途別（浄水、空気清浄、セルフクリーニング、その他）、地域別予測Global Photocatalyst Market to reach USD 4.49 billion by 2025. Global Photocatalyst Market valued approximately USD 1.70 billion in 2016 is forecasted to grow with a healthy growth rate of more than 11.41% over the forecast period 2018-2025. The major factors speculated to augment the markets are rising demand for low VOC coatings in the building & construction industry, and growing water scarcity …
- EMVカードの世界市場2016-2020About EMV EMV is a standard for payment cards, payment terminals, and automated teller machines (ATMs). The EMV standard was developed to deliver a safe and secure payment transaction between chip-based payment cards and terminals. A dynamic code is generated for every transaction when an EMV card is inserted into an EMV point-of-sale (POS) terminal. This is the prime benefit of EMV cards as it be …
- プラズモニック太陽電池の分析：Analyzing Plasmonic Solar CellsThe Sun, believed by the mankind to be just a mere centerpiece of the solar system in which we live is in reality not just a unit but an entire symphonic system which was in place much before the first humans ever walked on planet earth. This system which has been the primary energy source for origin of life on earth is in fact very well adequately positioned by nature to fulfill the needs of ener …
- Bisphenol E cyanate Easterの世界市場Bisphenol E cyanate Easter (CAS 47073-92-7) Market Research Report 2013 presents comprehensive data on bisphenol e cyanate easter markets globally and regionally (Europe, Asia, North America etc.) The Bisphenol E cyanate Easter (CAS 47073-92-7) Market Research Report 2013 includes bisphenol e cyanate easter description, covers its application areas and related patterns. It overviews bisphenol e cy …
- 止血および組織密閉剤の世界市場分析：製品別（局所的止血剤、アクティブ、機械的、流動性止血剤、接着剤、組織シーラント、合成組織シーラント、天然組織シーラント、接着バリア製品）、セグメント予測The global hemostasis and tissue sealing agents market is expected to reach USD 7.4 billion by 2022, according to a new report by Grand View Research Inc. The global hemostasis and tissue sealing agents market has gained popularity over time due to its ability in preventing blood loss. Rapid growth of minimal invasive technology and rising demand for faster recovery by patients is expected to prom …
- 水素生成の世界市場予測（～2022年）The global hydrogen generation market is projected to grow at a CAGR of 6.07%, from 2017 to 2022, to reach a market size of USD 154.74 Billion by 2022. This growth is attributed to government regulations for the desulfurization of petroleum products and a rising demand for hydrogen as a transportation fuel. The report segments the hydrogen generation market, by generation type, into captive and me …
- 輪転グラビア印刷用インクの世界市場：ニトロセルローズ、ポリアミド、ポリウレタン、アクリルThe global market size of rotogravure printing inks is projected to reach USD 4.30 Billion by 2021, registering a CAGR of 4.99% between 2016 and 2021. The growing manufacturing and end-use industries and the increasing flexible packaging application is driving the demand for rotogravure printing inks in the Asia-Pacific region and also the continuous product development, expansion, and merger & ac …
- グローバル・デジタルカメラ市場動向（2014-2018）About Digital Cameras A digital camera is an optical device which is used to capture images and videos. These images and videos are saved in digital format, unlike traditional cameras, where the images are stored on photographic film. Digital cameras can be classified into built-in lens cameras, such as point-and-shoot cameras, and interchangeable lens cameras, such as DSLRs and MILCs. A DSLR came …
- 全地球航法衛星システム（GNSS）の世界市場Global Navigation Satellite System (GNSS) is a technology that allows any user having a compatible device to determine their position, velocity and local time by processing signals from satellites in space. GNSS signals are provided by a variety of satellite positioning systems, including GPS, Galileo, Glonass, BeiDou or regional SBAS. The GNSS market comprises both products (receivers and devices …
- 加速度計およびジャイロスコープの世界市場展望2017-20276According to Stratistics MRC, the Global Accelerometer and Gyroscope is accounted for $ 1.71 billion in 2017 and is expected to reach $2.76 billion by 2026 growing at a CAGR of 4.9% during the forecast period. Increase in demand for consumer electronics, rise in number of vehicles globally, and high military spending are the key driving factors for the market growth. However, low accuracy acts as …
- 尿失禁関連デバイスの世界市場2019-2023About this market The growing prevalence of physical and medical conditions leading to urinary incontinence will further trigger the market’s growth in the forthcoming years. Strong prevalence of the elderly population in both emerging and advanced economies will further surge the incidences of urinary incontinence during the forecast period. Factors including spinal injury, pregnancy, menopause, …
- アニリンの世界市場動向及び予測2015The present report is an essential resource for a one looking for detailed information on the world aniline market. The report covers data on global, regional and national markets including present and future trends for supply and demand, prices, and downstream industries. In addition to the analytical part, the report provides a range of tables and figures which all together give a true insight i …
- 世界の固体レーザー市場（2014-2018）About Solid-state Lasers Solid-state lasers contain an active laser medium that is a solid that generally contains glass or crystals doped with rare earth elements. Solid-state lasers are preferred for numerous applications because they are more reliable, efficient, robust, and easier to operate than other lasers. They are largely used for cutting and welding purposes in industries such as Manufac …
- 世界の陽電子放射形コンピューター断層撮影法（PET）装置市場：医療機器パイプライン分析2016Positron Emission Tomography (PET) Systems - Medical Devices Pipeline Assessment, 2016 Summary GlobalData's Medical Devices sector report, “Positron Emission Tomography (PET) Systems - Medical Devices Pipeline Assessment, 2016" provides an overview of Positron Emission Tomography (PET) Systems currently in pipeline stage. The report provides comprehensive information on the pipeline products with …
- 白血病治療薬の世界市場：慢性リンパ性白血病、急性リンパ性白血病、急性骨髄性白血病、慢性骨髄性白血病About Leukemia Cancer that starts from hematopoietic stem cells of the bone marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. Also, based on the bone marrow cells from which cancer starts, leukemia can be categorized as lymphocytic or myeloid. Technavio’s analysts forecast the leukemia therapeutics market to grow at a CAGR of 8.44% during t …
